AstraZeneca

Gilead Sciences

Regeneron Pharmaceuticals

Incyte

Blueprint Medicines

Revolution Medicines

Illumina

Exelixis

Guardant Health Inc

SpringWorks Therapeutics Inc

Tema Oncology ETF

CANC is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations.

Loncar Cancer Immunotherapy ETF

Tema Obesity & Cardiometabolic ETF

iShares Genomics Immunology and Healthcare ETF

Roundhill GLP-1 & Weight Loss ETF

ALPS Medical Breakthroughs ETF

Amplify Weight Loss Drug & Treatment ETF

Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.

Disruptive Theme of the Week – Breakthroughs in Medicine

Oncology treatment has witnessed remarkable progress due to the relentless efforts of pharmaceutical companies in recent times.

Inside Tema ETFs' New Oncology ETF (CANC)

ASYMshares ASYMmetric 500 ETF

Asian Growth CUBS ETF

Grizzle Growth ETF

NightShares 500 1x/1.5x ETF

GraniteShares XOUT U.S. Large Cap ETF

Tema Global Royalties ETF

The U.S. ETF industry saw a major slowdown in ETF launches during the week ending Aug. 18 as the summer slump continued. Only six new ETFs launched, while issuers announced only one new closure.

This Week in ETFs: 2 New Funds Launch From Tema

NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”) launches two innovative and actively managed thematic ETF offerings: the Oncology ETF (CANC) and the Global Royalties ETF (ROYA). These strategies are the first to address these specific themes in an actively managed ETF wrapper in the United States. The CANC portfolio will be managed by David K. Song, MD, PhD, CFA, who has led biotechnology and healthcare investment teams throughout his extensive 25-year career, including roles at Rockefeller Capit.

Tema Launches Two Innovative, Active ETF Thematic Strategies: Oncology & Global Royalties

News for Tema Oncology ETF ETF (CANC)